{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:02:58Z","timestamp":1789984978739,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1124\/dmd.113.051151","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T02:02:58Z","timestamp":1360720978000},"page":"1012-1022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso\/Oxime Metabolite Formed via a Nitrone Intermediate"],"prefix":"10.1016","volume":"41","author":[{"given":"Joanna E.","family":"Barbara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.051151_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1124\/dmd.112.047027","article-title":"High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling","volume":"40","author":"Barbara","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/00498257109041503","article-title":"Metabolic oxidation of aliphatic basic nitrogen atoms and their alpha-carbon atoms","volume":"1","author":"Beckett","year":"1971","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.113.051151_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0090-9556(25)06096-9","article-title":"The formation of cytochrome P-450-metabolic intermediate complexes in microsomal fractions from extrahepatic tissues of the rabbit","volume":"4","author":"Buening","year":"1976","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.111.040949","article-title":"Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity","volume":"40","author":"Castellino","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib5","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/dmd.112.044958","article-title":"Interaction of lapatinib with cytochrome P450 3A5","volume":"40","author":"Chan","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0022-3565(25)32700-X","article-title":"Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450","volume":"218","author":"Danan","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.051151_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/138920005774330639","article-title":"Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity","volume":"6","author":"Fontana","year":"2005","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.113.051151_bib8","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","article-title":"Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer","volume":"26","author":"Gomez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.113.051151_bib9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1124\/dmd.110.032391","article-title":"Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem","volume":"38","author":"Hanson","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0026-895X(25)14349-6","volume":"23","author":"Jeffery","year":"1983","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib12","first-page":"313","article-title":"On the formation of cytochrome P-450 product complexes during the metabolism of phenylalkylamines","volume":"13","author":"Jonsson","year":"1976","journal-title":"Acta Pharm Suec"},{"key":"10.1124\/dmd.113.051151_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/chir.530040803","article-title":"Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependence in microsomes and reconstituted cytochrome P-450 systems from rat liver","volume":"4","author":"J\u00f6nsson","year":"1992","journal-title":"Chirality"},{"key":"10.1124\/dmd.113.051151_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/03602538209002232","article-title":"The non- and postenzymatic chemistry of N-oxygenated molecules","volume":"13","author":"Lindeke","year":"1982","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.113.051151_bib15","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/0006-2952(79)90409-X","article-title":"Cytochrome P-455 complex formation in the metabolism of phenylalkylamines\u2014IV. Spectral evidences for metabolic conversion of methamphetamine to N-hydroxyamphetamine","volume":"28","author":"Lindeke","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0090-9556(25)07961-9","article-title":"Cytochrome P-455-nm complex formation in the metabolism of phenylalkylamines. VI. Structure\u2014activity relationships in metabolic intermediary complex formation with a series of alpha-substituted 2-phenylethylamines and corresponding N-hydroxylamines","volume":"10","author":"Lindeke","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib17","first-page":"283","article-title":"Use of model systems in biochemical toxicology: heme models","volume":"3","author":"Mansuy","year":"1981","journal-title":"Biochem Toxicol"},{"key":"10.1124\/dmd.113.051151_bib18","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1021\/ja00461a046","article-title":"Nitrosoalkanes as new ligands of iron(II) porphyrins and hemoproteins","volume":"99","author":"Mansuy","year":"1977","journal-title":"J Am Chem Soc"},{"key":"10.1124\/dmd.113.051151_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0006-2952(76)90398-1","article-title":"The nature of the \u201c455 nm absorbing complex\u201d formed during the cytochrome P450 dependent oxidative metabolism of amphetamine","volume":"25","author":"Mansuy","year":"1976","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1432-1033.1978.tb12341.x","article-title":"Formation of complexes between microsomal cytochrome P-450-Fe(II) and nitrosoarenes obtained by oxidation of arylhydroxylamines or reduction of nitroarenes in situ","volume":"86","author":"Mansuy","year":"1978","journal-title":"Eur J Biochem"},{"key":"10.1124\/dmd.113.051151_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1432-1033.1977.tb11632.x","article-title":"Nitrosoalkanes as Fe(II) ligands in the hemoglobin and myoglobin complexes formed from nitroalkanes in reducing conditions","volume":"76","author":"Mansuy","year":"1977","journal-title":"Eur J Biochem"},{"key":"10.1124\/dmd.113.051151_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-2952(95)02105-1","article-title":"Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites","volume":"51","author":"McNeil","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/00498250310001602748","article-title":"Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines","volume":"33","author":"Murray","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.113.051151_bib24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2174\/156802611794480882","article-title":"Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development","volume":"11","author":"Nettleton","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.113.051151_bib25","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm300065h","article-title":"Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks","volume":"55","author":"Orr","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.113.051151_bib26","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.109.028274","article-title":"In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran","volume":"37","author":"Paris","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1124\/dmd.111.038596","article-title":"An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes","volume":"39","author":"Parkinson","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib28","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3748\/wjg.v17.i18.2349","article-title":"Lapatinib-induced hepatitis: a case report","volume":"17","author":"Peroukides","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1124\/dmd.113.051151_bib29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0006-2952(81)90125-8","article-title":"Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450","volume":"30","author":"Pessayre","year":"1981","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib30","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/0006-2952(82)90671-2","article-title":"Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans","volume":"31","author":"Pessayre","year":"1982","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2125.2007.02964.x","article-title":"Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants","volume":"65","author":"Polasek","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib32","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/0006-2952(72)90389-9","article-title":"Dimethylaminoethyl 2,2-diphenylvalerate HCl (SKF 525-A)\u2014in vivo and in vitro effects of metabolism by rat liver microsomes\u2014formation of an oxygenated complex","volume":"21","author":"Schenkman","year":"1972","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/clpt.2011.277","article-title":"Lapatinib-induced liver injury characterized by class II HLA and Gilbert\u2019s syndrome genotypes","volume":"91","author":"Spraggs","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.051151_bib34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1124\/dmd.110.037531","article-title":"Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib","volume":"39","author":"Takakusa","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051151_bib35","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/jcc.23008","article-title":"Metabolic-intermediate complex formation with cytochrome P450: theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate","volume":"33","author":"Taxak","year":"2012","journal-title":"J Comput Chem"},{"key":"10.1124\/dmd.113.051151_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1124\/mol.110.065839","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib","volume":"78","author":"Teng","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.113.051151_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/cr50021a001","article-title":"Oxidations by ferricyanide","volume":"58","author":"Thyagarajan","year":"1958","journal-title":"Chem Rev"},{"key":"10.1124\/dmd.113.051151_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/004982500237730","article-title":"Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem","volume":"30","author":"Trieu","year":"2000","journal-title":"Xenobiotica"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.051151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:40:15Z","timestamp":1739907615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624115802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0090955624115802"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.051151","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso\/Oxime Metabolite Formed via a Nitrone Intermediate","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.051151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}